One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition.
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.
“Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled ‘orphan diseases.’ We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases,” said Misagh Naderi, one of the paper’s lead authors and a doctoral candidate in the LSU Department of Biological Sciences.
This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.
“In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson’s disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease,” said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.
The Latest on: Drug repositioning
via Google News
The Latest on: Drug repositioning
- SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine developmenton August 5, 2022 at 7:32 am
SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development The present pandemic has posed a crisis to the economy of the world and the health sector.
- At 68, Marwa Continues to Distinguish Himself In Leadership, Says Buharion August 2, 2022 at 5:00 pm
President Buhari noted the fillip in the war against drug abuse and trafficking, with commendable results, appreciating Marwa’s dedication to repositioning the NDLEA, sanitizing the streets and ...
- Repositioning Therapeutic Cancer Vaccines in the Dawning Era of Potent Immune Interventionson August 1, 2022 at 5:00 pm
 CML patients on chronic treatment with the tyrosine kinase inhibitor imatinib mesylate (Gleevec®), responding to this drug, were vaccinated and monitored using the bcr/abl marker ...
- Repositioning Healthcare Deliveryon July 29, 2022 at 5:00 pm
Drug availability is also a cause for concern, with less than half of all Primary Healthcare Centre (PHC) facilities having the listed essential drugs in stock. Healthcare is majorly driven by the ...
- Repositioning Dislocated Temporomandibular Jointson July 20, 2022 at 5:00 pm
Figure 2. Figure 2. Placement of the Hands during the Repositioning of the First Temporomandibular Joint. Reposition the mandible one side at a time. Fix the patient's head between your body and ...
- Rudin Completes Two Long-Term Leases Totaling More Than 36,000 Square Feet at 80 Pine Street in Lower Manhattanon July 20, 2022 at 10:48 am
a 1.2-million-square-foot office tower that is in the final stages of a major repositioning. The Global Alliance for TB Drug Development, Inc. (TB Alliance) signed a 16-year, 21,561 square-foot ...
- STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Projecton July 19, 2022 at 3:43 am
STALICLA DDS was granted a EUR 1.7 million budget over 6 years to act as leader for in silico drug repositioning work tasks. STALICLA DDS will bring its technology and know-how to analyze biosample ...
- STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Projecton July 19, 2022 at 3:20 am
STALICLA DDS was granted a EUR 1.7 million budget over 6 years to act as leader for in silico drug repositioning work tasks. STALICLA DDS will bring its technology and know-how to analyze ...
- Drug Repositioning Market Size estimated 36385.53 million with CAGR of 4.75%, Current Insights and Development Trends Report, 2022-2028on July 11, 2022 at 10:48 pm
Jul 12, 2022 (The Expresswire) -- Drug Repositioning Market Research’s latest report provides a deep insight into the global Drug Repositioning market covering all its essential aspects.
via Bing News